First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck canc

[News]

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.

More... (http://www.news-medical.net/news/20140121/First-patient-dosed-in-ADXS-HPV-Phase-12-study-for-HPV-associated-head-and-neck-cancer.aspx)